vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $242.1M, roughly 1.5× ONESPAWORLD HOLDINGS Ltd). LivaNova PLC runs the higher net margin — 8.6% vs 5.0%, a 3.6% gap on every dollar of revenue. On growth, LivaNova PLC posted the faster year-over-year revenue change (12.1% vs 11.5%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $14.9M). Over the past eight quarters, LivaNova PLC's revenue compounded faster (10.6% CAGR vs 7.1%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
LIVN vs OSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $242.1M |
| Net Profit | $30.9M | $12.1M |
| Gross Margin | 65.2% | — |
| Operating Margin | 11.8% | 6.8% |
| Net Margin | 8.6% | 5.0% |
| Revenue YoY | 12.1% | 11.5% |
| Net Profit YoY | -44.7% | -16.2% |
| EPS (diluted) | $0.57 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $242.1M | ||
| Q3 25 | $357.8M | $258.5M | ||
| Q2 25 | $352.5M | $240.7M | ||
| Q1 25 | $316.9M | $219.6M | ||
| Q4 24 | $321.8M | $217.2M | ||
| Q3 24 | $318.1M | $241.7M | ||
| Q2 24 | $318.6M | $224.9M | ||
| Q1 24 | $294.9M | $211.2M |
| Q4 25 | $30.9M | $12.1M | ||
| Q3 25 | $26.8M | $24.3M | ||
| Q2 25 | $27.2M | $19.9M | ||
| Q1 25 | $-327.3M | $15.3M | ||
| Q4 24 | $55.9M | $14.4M | ||
| Q3 24 | $33.0M | $21.6M | ||
| Q2 24 | $16.3M | $15.8M | ||
| Q1 24 | $-41.9M | $21.2M |
| Q4 25 | 65.2% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 69.7% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 70.8% | — | ||
| Q2 24 | 68.7% | — | ||
| Q1 24 | 70.3% | — |
| Q4 25 | 11.8% | 6.8% | ||
| Q3 25 | 15.1% | 10.2% | ||
| Q2 25 | 15.4% | 9.2% | ||
| Q1 25 | 15.3% | 7.7% | ||
| Q4 24 | 11.5% | 7.9% | ||
| Q3 24 | 11.2% | 10.3% | ||
| Q2 24 | 12.6% | 8.4% | ||
| Q1 24 | 5.5% | 8.0% |
| Q4 25 | 8.6% | 5.0% | ||
| Q3 25 | 7.5% | 9.4% | ||
| Q2 25 | 7.7% | 8.3% | ||
| Q1 25 | -103.3% | 7.0% | ||
| Q4 24 | 17.4% | 6.6% | ||
| Q3 24 | 10.4% | 8.9% | ||
| Q2 24 | 5.1% | 7.0% | ||
| Q1 24 | -14.2% | 10.0% |
| Q4 25 | $0.57 | $0.12 | ||
| Q3 25 | $0.49 | $0.23 | ||
| Q2 25 | $0.50 | $0.19 | ||
| Q1 25 | $-6.01 | $0.15 | ||
| Q4 24 | $1.04 | $0.13 | ||
| Q3 24 | $0.60 | $0.20 | ||
| Q2 24 | $0.30 | $0.15 | ||
| Q1 24 | $-0.78 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $16.3M |
| Total DebtLower is stronger | $376.1M | $84.0M |
| Stockholders' EquityBook value | $1.2B | $542.6M |
| Total Assets | $2.6B | $707.1M |
| Debt / EquityLower = less leverage | 0.31× | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $16.3M | ||
| Q3 25 | $646.1M | $29.6M | ||
| Q2 25 | $593.6M | $35.0M | ||
| Q1 25 | $738.4M | $22.6M | ||
| Q4 24 | $428.9M | $57.4M | ||
| Q3 24 | $346.4M | $48.8M | ||
| Q2 24 | $329.2M | $62.5M | ||
| Q1 24 | $309.2M | $65.4M |
| Q4 25 | $376.1M | $84.0M | ||
| Q3 25 | $434.5M | $85.2M | ||
| Q2 25 | $430.6M | $96.2M | ||
| Q1 25 | $628.2M | $97.4M | ||
| Q4 24 | $627.0M | $98.6M | ||
| Q3 24 | $625.5M | $98.7M | ||
| Q2 24 | $624.5M | $123.8M | ||
| Q1 24 | $623.8M | $138.6M |
| Q4 25 | $1.2B | $542.6M | ||
| Q3 25 | $1.2B | $552.8M | ||
| Q2 25 | $1.1B | $548.3M | ||
| Q1 25 | $1.0B | $530.6M | ||
| Q4 24 | $1.3B | $554.5M | ||
| Q3 24 | $1.3B | $540.1M | ||
| Q2 24 | $1.2B | $532.7M | ||
| Q1 24 | $1.2B | $515.5M |
| Q4 25 | $2.6B | $707.1M | ||
| Q3 25 | $2.6B | $732.6M | ||
| Q2 25 | $2.5B | $731.8M | ||
| Q1 25 | $2.6B | $708.7M | ||
| Q4 24 | $2.5B | $746.4M | ||
| Q3 24 | $2.5B | $734.0M | ||
| Q2 24 | $2.5B | $756.8M | ||
| Q1 24 | $2.5B | $763.6M |
| Q4 25 | 0.31× | 0.15× | ||
| Q3 25 | 0.38× | 0.15× | ||
| Q2 25 | 0.38× | 0.18× | ||
| Q1 25 | 0.61× | 0.18× | ||
| Q4 24 | 0.47× | 0.18× | ||
| Q3 24 | 0.48× | 0.18× | ||
| Q2 24 | 0.50× | 0.23× | ||
| Q1 24 | 0.51× | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $20.0M |
| Free Cash FlowOCF − Capex | $50.2M | $14.9M |
| FCF MarginFCF / Revenue | 13.9% | 6.2% |
| Capex IntensityCapex / Revenue | 8.9% | 2.1% |
| Cash ConversionOCF / Net Profit | 2.67× | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $20.0M | ||
| Q3 25 | $85.1M | $33.2M | ||
| Q2 25 | $62.9M | $20.3M | ||
| Q1 25 | $24.0M | $10.1M | ||
| Q4 24 | $78.7M | $16.6M | ||
| Q3 24 | $51.0M | $28.6M | ||
| Q2 24 | $43.4M | $18.7M | ||
| Q1 24 | $10.0M | $15.0M |
| Q4 25 | $50.2M | $14.9M | ||
| Q3 25 | $62.2M | $27.6M | ||
| Q2 25 | $47.8M | $17.6M | ||
| Q1 25 | $13.2M | $8.4M | ||
| Q4 24 | $68.3M | $13.2M | ||
| Q3 24 | $32.8M | $27.5M | ||
| Q2 24 | $31.2M | $17.6M | ||
| Q1 24 | $3.6M | $13.7M |
| Q4 25 | 13.9% | 6.2% | ||
| Q3 25 | 17.4% | 10.7% | ||
| Q2 25 | 13.6% | 7.3% | ||
| Q1 25 | 4.2% | 3.8% | ||
| Q4 24 | 21.2% | 6.1% | ||
| Q3 24 | 10.3% | 11.4% | ||
| Q2 24 | 9.8% | 7.8% | ||
| Q1 24 | 1.2% | 6.5% |
| Q4 25 | 8.9% | 2.1% | ||
| Q3 25 | 6.4% | 2.2% | ||
| Q2 25 | 4.3% | 1.1% | ||
| Q1 25 | 3.4% | 0.8% | ||
| Q4 24 | 3.2% | 1.5% | ||
| Q3 24 | 5.7% | 0.5% | ||
| Q2 24 | 3.8% | 0.5% | ||
| Q1 24 | 2.2% | 0.6% |
| Q4 25 | 2.67× | 1.65× | ||
| Q3 25 | 3.18× | 1.36× | ||
| Q2 25 | 2.32× | 1.02× | ||
| Q1 25 | — | 0.66× | ||
| Q4 24 | 1.41× | 1.15× | ||
| Q3 24 | 1.55× | 1.33× | ||
| Q2 24 | 2.65× | 1.19× | ||
| Q1 24 | — | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
